Roche Holding Ltd

40.86

+0.10000.25%

Post-market: 40.860.00000.00%16:00 EDT

Volume:979.09K

Turnover:39.88M

Market Cap:264.53B

PE:26.35

High:40.89

Open:40.51

Low:40.51

Close:40.76

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk

Dow Jones

·

03 Jun

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RHHBY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":40.86,"timestamp":1749240000000,"preClose":40.76,"halted":0,"volume":979086,"hourTrading":{"tag":"盘后","latestPrice":40.86,"preClose":40.86,"latestTime":"16:00 EDT","volume":149,"amount":6088.14,"timestamp":1749240005714},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Market Closed","change":0.1,"latestTime":"06-06 16:00:00 EDT Delay","open":40.51,"high":40.89,"low":40.51,"amount":39881288.591699965,"amplitude":0.009323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":40.76,"volumeRatio":0.9515158288218268},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":0.9515158288218268,"shares":6474029800,"dividePrice":1.34,"high":40.89,"amplitude":0.009323,"preClose":40.76,"low":40.51,"week52Low":33.3,"pbRate":"6.84","psRate":"3.48","week52High":44.31,"institutionHeld":0,"latestPrice":40.86,"eps":1.550894,"divideRate":0.032795,"volume":979086,"delay":15,"ttmEps":1.550894,"open":40.51,"prevYearClose":34.88,"prevWeekClose":40.3,"prevMonthClose":40.3,"prevQuarterClose":41.15,"fiveDayClose":40.3,"twentyDayClose":39.11,"sixtyDayClose":43.56},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RHHBY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540728789","title":"Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2540728789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540728789?lang=en_us&edition=fundamental","pubTime":"2025-06-03 15:51","pubTimestamp":1748937060,"startTime":"0","endTime":"0","summary":"0749 GMT - Revenue from Roche's Tecentriq drug is unlikely to significantly increase despite data showing that in combination with lurbinectedin, it prolongs the life of patients with small-cell lung cancer, Vontobel analyst Stefan Schneider writes. Tecentriq was already approved in 2019 for use in combination with chemotherapy, he writes. Data from Roche shows that the median progression-free survival time was 5.4 months for the combination versus 2.1 months in the Tecentriq-alone arm, he writes. While this is an improvement, there is clearly room for more, he writes. Shares trade down 0.4% at 283.10 Swiss francs. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2540136847","title":"Genentech reports ‘positive’ results from Phase III IMforte study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540136847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540136847?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:11","pubTimestamp":1748895064,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced positive results from the Phase III IMforte study of Tecentriq in combination with lurbin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-reports-positive-results-from-phase-iii-imforte-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-reports-positive-results-from-phase-iii-imforte-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","III","BK4134","03165"],"gpt_icon":0},{"id":"2540792535","title":"Roche Holding AG Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2540792535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540792535?lang=en_us&edition=fundamental","pubTime":"2025-06-03 00:17","pubTimestamp":1748881020,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  slid 0.3% to CHF264.70 Monday on what proved to be an overall poor trading session for the stock market, with the Swiss SMI Index  falling 0.2% to 12,198.18.Roche Holding AG closed CHF49.10 short of its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 679,647, compared to the 50-day average trading volume of 1,433,980.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2540384730","title":"Genentech announces final results from OS analysis of Phase III INAVO120 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540384730","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540384730?lang=en_us&edition=fundamental","pubTime":"2025-06-02 03:55","pubTimestamp":1748807710,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced positive final results from the overall survival, OS, analysis of the Phase III INAVO120 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-announces-final-results-from-os-analysis-of-phase-iii-inavo120-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-announces-final-results-from-os-analysis-of-phase-iii-inavo120-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","RHHBY","BK4007","BK4134","03165"],"gpt_icon":0}],"pageSize":4,"totalPage":29,"pageCount":1,"totalSize":114,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-07-24","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753344000000,"name":null,"time":"Pre-Market","dateTimestamp":1753329600000,"actualEps":null},{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}